Treatments

*October 2025* Dr Alfredo Addeo (University Hospital of Geneva, Geneva, Switzerland), Prof Nicolas Girard (Institut Curie, Paris, France), Dr Anna Minchom (Institute of Cancer Research, London, UK) and Prof Pascale Tomasini (Aix-Marseille University, Marseille, France) discuss the latest advances in EGFR-mutant non-small cell lung cancer (NSCLC). The panel reviews newly…

*December 2025* Abstract Purpose Lazertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has demonstrated high blood–brain barrier (BBB) penetration in preclinical studies. Similarly, pemetrexed has shown effective BBB penetration and survival benefit in EGFR-mutant non-small cell lung cancer (NSCLC) with leptomeningeal carcinomatosis (LM). This study evaluated the…

*October 2025* BlossomHill Therapeutics, Inc., a privately-held, a clinical-stage biopharmaceutical company focused on the design and development of next-generation medicines for cancer, today presented preliminary findings from the dose escalation portion of the company’s ongoing, first-in-human Phase 1/2 SOLARA trial of BH-30643 in patients with locally advanced or metastatic EGFR-mutant…

*October 2025* As therapies advance and patients are living longer, brain metastases and leptomeningeal disease have become a growing concern for individuals diagnosed with lung cancer. Identification and treatment of these conditions are developing to meet this serious unmet need. Join Drs Laura Alder (thoracic oncologist) and Trey Mullikin (oncology…

*October 2025* Abstract Background Despite the intracranial efficacy of osimertinib, central nervous system (CNS) metastases remain a major cause of morbidity and mortality in EGFR-mutant non-small-cell lung cancer (NSCLC). The genomic drivers of CNS dissemination are poorly understood. Patients and methods We analyzed the clinicogenomic features of patients with EGFR-mutant NSCLC receiving…

*September 2025* Abstract Introduction Uncommon EGFR mutations comprise 10% to 20% of all EGFR mutations in NSCLC and generally report reduced responsiveness to EGFR tyrosine kinase inhibitors (TKIs). Lazertinib, a third-generation EGFR-TKI, has found efficacy in common EGFR mutations, but its potential in uncommon mutations remains unexplored. This study investigated the efficacy and safety of lazertinib…

*October 2025* Highlights • EGFR 19delins variants show varied outcomes with third-generation EGFR-TKI therapy. • L747_P753delinsS associated with poor prognosis among EGFR 19delins variants. • E746_S752delinsV showed better outcomes with third-generation EGFR-TKI. Abstract Purpose The sensitivity of various epidermal growth factor receptor (EGFR) mutations to different EGFR tyrosine kinase inhibitors (EGFR-TKI) varies…

*October 2025* Join us in this episode of the Oncology Brothers podcast as we dive into the highlights from the World Conference on Lung Cancer 2025! We are joined by Dr. Balazs Halmos, a thoracic medical oncologist at the Montefiore Einstein Cancer Center, to discuss three pivotal studies that are…

*September 2025* The ACROSS 2 trial comparing aumolertinib, a third-generation EGFR-TKI, with and without platinum-based chemotherapy, found that combination therapy improved progression-free survival (PFS) for patients with EGFR-mutated non-small cell lung cancer (NSCLC) who also had co-mutated tumor suppressor genes (TSGs). The PFS benefit was modest, 19.8 months for combination…

*September 2025* This is the slide deck from AstraZeneca's Global Lung Cancer Advocacy Exchange at the 2025 WCLC in Barcelona. You can access the slides here.